ProfileGDS5678 / 1436792_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 64% 63% 65% 61% 63% 64% 63% 63% 63% 63% 63% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7996963
GSM967853U87-EV human glioblastoma xenograft - Control 23.798764
GSM967854U87-EV human glioblastoma xenograft - Control 33.7950363
GSM967855U87-EV human glioblastoma xenograft - Control 43.9477265
GSM967856U87-EV human glioblastoma xenograft - Control 53.5968561
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8305463
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8906964
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7753263
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7776363
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7917863
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7767763
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7734363
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7838963
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7891963